CORAL GABLES, FL / ACCESSWIRE / February 5, 2019 / The marijuana stock market has seen impressive gains over the last few weeks of the new year, with companies in the space seeing large increases in their stock prices. The market has been shifting rapidly for some time largely because of new legislation being brought to the table in favor of legalizing marijuana, as well as an overall paradigm shift in how the public views cannabis and companies which research, cultivate, manufacture, and distribute a product. The increase of capital, in tandem with growing public approval, has resulted in the cannabis sector attracting more investors looking for potential opportunities. As we see what February has in store, Leafbuyer Technologies Inc (OTC:LBUY), MariMed Inc (MRMD), Tilray Inc (TLRY), and INSYS Therapeutics (INSY) are 4 pot stocks worth looking into on Tuesday.
Leafbuyer Technologies Inc (OTC:LBUY) is one of the leading online resources for those in the cannabis industry. The Company, through its subsidiary, LB Media Group LLC, operates an online platform for trending cannabis deals and specials and has been lauded as the most comprehensive source for ascertaining cannabis-related information.
As more consumers have been shifting towards conducting their own research into brands they are interested in, a Company like Leafbuyer Technologies Inc (OTC:LBUY) stands above its competitors. The Company's platform has been referred to as the "priceline of pot" by cannabis experts and analysts in the industry, because of the ease of access for consumers looking to learn, find, or research anything about the cannabis market.
Leafbuyer Technologies Inc (OTC:LBUY) announced towards the end of last month that its quarterly sales rose 68% in the quarter ending December 31, 2018. The increase reflects the revenues booked in the quarter versus the same quarter of the previous year.
Mark Breen, Chief Operating Officer of Leafbuyer Technologies Inc (OTC:
MariMed Inc (MRMD), a leading multi-state cannabis operator, announced in mid-January that the Company had formed MariMed Hemp Inc, a wholly-owned subsidiary to be entirely focused on hemp-derived CBD products. MariMed Hemp will have a dedicated executive team, proprietary brand and product lines, and distribution and marketing relationships, all separate from MariMed's core cannabis business.
Following the announcement of their subsidiary formation, Robert Fireman, CEO of MariMed, said, "With the recent signing of the U.S. Farm Bill that declared hemp fully legal at the federal level, we believe the hemp CBD industry may grow even faster than the cannabis industry. Consumers and retailers alike seek the highest quality, trustworthy products. While many niche players may try to compete, the reality is that only a handful of suppliers can reliably deliver top-quality CBD products at a scale that can serve the needs of major retailers."
Tilray Inc (TLRY), a global leader in cannabis production, research, cultivation, and distribution managed to rise above other companies in the cannabis sector by enjoying a 1.12% boost in late-morning trading on Tuesday, with shares trading at $83.78 per share. At the tail-end of last month, the Company announced the expansion of its global leadership team with four new hires: Greg Christopher as EVP of Operations, formerly with Nestle; Rita Seguin as EVP of Human Resources, formerly with Diageo; Dara Redler as General Counsel, formerly with The Coca-Cola Company; and Charlie Cain as VP of Retail, formerly with Starbucks Corporation.
Following the announcement of the new appointees, Tilray's CEO, Brendan Kennedy, said, "Greg, Rita, Dara, and Charlie come to Tilray with robust expertise in their respective fields and we look forward to their contributions as we pioneer the future of cannabis around the world."
INSYS Therapeutics Inc (INSY) saw impressive gains on Tuesday morning as Company shares soared 13.94%, trading at $4.52 per share just before noon. Just after the new year, the Company, which focuses on the development and manufacturing of pharmaceutical cannabinoids and spray technology, announced the results of a dose-finding pharmacokinetic (PK) study (INS015-18-124) of its epinephrine nasal spray. These results identified a dose that showed a PK profile similar to that of intramuscular injection of EpiPen® (0.3 mg) and Adrenalin® (0.5 mg), both of which are treatments for anaphylaxis, an acute, life-threatening allergic reaction.
Dr. Venkat Goskonda, Senior Vice President of Research and Development at INSYS, commented, "the results of our proof-of-concept (INS015-17-112) and dose-finding (INS015-18-124) studies confirmed that INSYS' novel, proprietary formulation of epinephrine delivered intra-nasally potentially offers a viable, attractive alternative and non-invasive delivery option to the currently marketed products."
MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana-related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MAPH Enterprises LLC which owns www.MarijuanaStocks.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), Midam Ventures LLC and Leafbuyer Technologies Inc., Midam is being paid $50,000 for a period of 30 days beginning November 1, 2018, and ending November 30, 2018. Midam has been paid an additional $50,000 and 40,000 common restricted shares of Leafbuyer Technologies, Inc. extending the contract another 30 days ending December 31, 2018. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to January 31, 2019. We own 77,000 shares of Leafbuyer Technologies. We may buy or sell additional shares of (LBUY) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Leafbuyer Technologies Inc. For previous compensation and disclaimer information, click here.
View source version on accesswire.com: